logo
Wes Streeting office vandalised with windows smashed

Wes Streeting office vandalised with windows smashed

The National5 days ago
A trans rights group – who call themselves Bash Back – has taken credit and shared a series of images to social media site BlueSky this afternoon which show the front of the Health Secretary's office.
Spraypainted on one window are the words "child killer" while several other windows appear to also be smashed.
The post (below) reads: 'We refuse to sit and watch as trans young people have their healthcare stripped from them. We refuse to allow Streeting to cover up their suicides. We refuse to endure the violence and humiliation. They will have to go through us.'
Our statement on the actions at Wes Streeting's office last night. We refuse to sit and watch as trans young people have their healthcare stripped from them. We refuse to allow Streeting to cover up their suicides. We refuse to endure the violence and humiliation. They will have to go through us.
[image or embed] — BASH BACK (@bashback.bsky.social) 1 August 2025 at 13:39
A statement was also released which said it was in response to his "continued abuse of trans people in the medical system, and attempts to cover up the suicides of trans young people under his watch as Health Secretary".
Streeting, meanwhile, condemned the vandalism and said it was "unfair" to his staff and an "attack on democracy".
The NHS announced in March last year that children would no longer be prescribed puberty blockers at gender identity clinics.
In May, following the publication of the Cass Review, the Conservative government introduced a ban with emergency legislation, preventing the prescription of the medication from European or private prescribers and restricting NHS provision to within clinical trials.
The move was then made indefinite in December under the new Labour Government – with Streeting as Health Secretary.
He said in April this year that he is 'genuinely sorry' for the 'fear and anxiety' felt by the transgender community following the ban.
But he added: 'I would challenge anyone in my shoes to say, as a politician, that you would overrule clinical advice, especially when it comes to medicines that are challenged on the basis of whether they are safe or not for children.
'I know people disagree with that decision. I know it's caused real fear and anxiety in our community, and that certainly doesn't sit easy with me.'
Commenting on the vandalism, Streeting said: "From day one as Ilford North's MP I've had an accessible and visible constituency office to serve my local community.
"Repeated criminal damage is unfair to my staff and an attack on democracy.I will not be commenting further while there is a live police investigation."
The Met Police have been approached for comment.
The full statement from Bash Back reads: "On July 31st, a group of activists representing BASH BACK took action against Wes Streeting's office in Ilford, in response to his continued abuse of trans people in the medical system, and attempts to cover up the suicides of trans young people under his watch as Health Secretary.
"In the months since the puberty blockers ban, we have seen huge backpedals in the healthcare rights afforded to trans people and young people especially - in an NHS system that was never kind to us in the first place.
"Under Streeting's rule, GPs have been banned from conducting blood tests on trans patients accessing HRT, and trans people have been banned from accessing hospital wards that fit their gender, leading necessarily to poorer quality of care across the board.
"Streeting, along with NHS England, the EHRC, and Hilary Cass, have paved the way for state-mandated conversion therapy, which has since led to the Department for Education's proposed introduction of a Section 28 style bill, preventing discussion of transness in the classroom.
"It is clear now that Wes Streeting and the Labour government intend to erase trans people from public life, and will go out of their way to do so, no matter how many bodies lay in their path."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

The Independent

time41 minutes ago

  • The Independent

Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust

More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.

Donald Trump to meet Putin with Zelensky for face to face Ukraine peace talks
Donald Trump to meet Putin with Zelensky for face to face Ukraine peace talks

Daily Mirror

time42 minutes ago

  • Daily Mirror

Donald Trump to meet Putin with Zelensky for face to face Ukraine peace talks

Donald Trump could hold an in-person meeting with Vladimir Putin and Volodymyr Zelensky after branding Russia an 'extraordinary threat' to the US and slapping sanctions on India. Putin held talks with Trump's special envoy Steve Witkoff in Moscow today, the Kremlin said, just days before the White House's deadline for Russia to reach a peace deal with Ukraine or potentially face severe economic penalties that could also hit countries buying its oil. Since, Trump is understood to have told European leaders including Sir Keir Starmer that he could meet with Putin, before a potential trilateral meeting with the Ukrainian president. It remains unclear if Putin and Zelensky have agreed to the idea, which was reported by The New York Times earlier today. Follow our live blog below for the latest updates. 21:06Benjamin Lynch Zelensky on call with European leaders Zelensky was on the call with Starmer and other European leaders including NATO secretary general Mark Rutte and German chancellor Friedrich Merz. On social media, Zelensky said the war must come to an end in a way that is done 'honestly' and that leaders 'discussed what was spelled out in Moscow' during the call. 'Ukraine will definitely defend its independence,' he said. 'We all need a lasting and reliable peace. Russia must end the war that it itself started. Thank you to everyone who stands with Ukraine.' 21:06Benjamin Lynch Trump 'proposes talks with Putin and Zelensky' Trump is understood to have told European leaders including Sir Keir Starmer that he could meet with Putin, before a potential trilateral meeting with Ukrainian President Volodymyr Zelensky. It remains unclear if Putin and Zelensky have agreed to the idea, which was reported by The New York Times earlier today.

European shares end flat as healthcare stocks weigh after Trump's tariff threat
European shares end flat as healthcare stocks weigh after Trump's tariff threat

Reuters

timean hour ago

  • Reuters

European shares end flat as healthcare stocks weigh after Trump's tariff threat

Aug 6 (Reuters) - European shares closed flat on Wednesday, surrendering early session gains, as healthcare stocks felt the pinch from U.S. President Donald Trump's latest threat to impose higher tariffs on pharmaceutical imports. The pan-European STOXX 600 (.STOXX), opens new tab index closed 0.06% lower, breaking its two-day winning streak despite starting the session on a positive note. Healthcare stocks bore the brunt of the selling pressure. The sector index (.SXDP), opens new tab plunged 2.8% to its lowest level in more than three months after Trump unveiled a graduated tariff plan targeting pharmaceutical imports that could see levies on the sector jump up to 250% within 18 months. "This is where it's important to be specific about tariffs because certain stocks and sectors will be impacted differently across regions," said Steve Sosnick, chief market analyst at Interactive Brokers. "In Europe and Asia, investors are considering tariff impacts more carefully since exporters bear much of the brunt directly." The sector was also singed as Novo Nordisk ( opens new tab warned it expects continued competition from copycat versions of its Wegovy obesity drug this year, a message that sent shares of the Danish drug maker down 5.4%. Novo cut its full-year sales and profit forecasts last week, wiping $95 billion off its market value since then. Meanwhile, Swiss President Karin Keller-Sutter met with U.S. Secretary of State Marco Rubio to discuss potential trade solutions after Trump announced a 39% tariff on Swiss goods. The talks focused on increasing Swiss purchases of U.S. energy and defence products to avert the steep tariff, which threatens significant damage to Switzerland's export-driven economy. Switzerland's benchmark SMI index (.SSMI), opens new tab fell 0.9%, weighed down by drugmakers Novartis (NOVN.S), opens new tab and Roche (ROG.S), opens new tab which lost 3.3% and 2.6%, respectively. Bayer ( opens new tab shares tumbled 9.9% on investor concerns that the German pharmaceutical firm's earnings were inflated by soccer player transfer fees rather than supported by its core healthcare and agriculture businesses. On the data front, Euro zone retail sales grew quicker than thought in June, reinforcing views that the 27-nation bloc remains resilient to trade uncertainty. Among others, Beiersdorf ( opens new tab fell 8.4% and was among top decliners after the German consumer goods maker cut its annual organic sales growth outlook. On the flip side, Siemens Energy ( opens new tab rose 1% after the company said it expects to hit the upper end of its 2025 growth outlook estimates. Hiscox (HSX.L), opens new tab was the top gainer on the index, gaining 9.4% after reporting a rise in first-half insurance premiums supported by its retail business growth.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store